Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.

Rogers TM, Arnau GM, Ryland GL, Huang S, Lira ME, Emmanuel Y, Perez OD, Irwin D, Fellowes AP, Wong SQ, Fox SB.

Sci Rep. 2017 Feb 9;7:42259. doi: 10.1038/srep42259.

2.

Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer.

Pancewicz-Wojtkiewicz J.

Cancer Med. 2016 Dec;5(12):3572-3578. doi: 10.1002/cam4.944. Review.

3.

Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.

Slade RL, Pisaneschi F, Nguyen QD, Smith G, Carroll L, Beckley A, Kaliszczak MA, Aboagye EO.

PLoS One. 2016 Aug 23;11(8):e0161427. doi: 10.1371/journal.pone.0161427.

4.

Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.

Uzhachenko R, Shanker A.

Oncoimmunology. 2016 Jan 11;5(5):e1122864. doi: 10.1080/2162402X.2015.1122864.

5.

A genetic cell context-dependent role for ZEB1 in lung cancer.

Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y.

Nat Commun. 2016 Jul 26;7:12231. doi: 10.1038/ncomms12231.

6.
7.

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.

Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ, Park WY.

J Pathol Transl Med. 2016 Jul;50(4):258-63. doi: 10.4132/jptm.2016.04.19.

8.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567.

9.

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.

Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C.

Oncotarget. 2016 May 10;7(19):28748-60. doi: 10.18632/oncotarget.7638. Review.

10.

Somatic DNA mutation analysis in targeted therapy of solid tumours.

Yu B, O'Toole SA, Trent RJ.

Transl Pediatr. 2015 Apr;4(2):125-38. doi: 10.3978/j.issn.2224-4336.2015.04.04. Review.

11.

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.

Xu MM, Pu Y, Zhang Y, Fu YX.

Trends Immunol. 2016 Feb;37(2):141-53. doi: 10.1016/j.it.2015.12.007. Review.

12.

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.

Kim WJ, Kim S, Choi H, Chang J, Shin HJ, Park CK, Oh IJ, Kim KS, Kim YC, Choi YD.

Thorac Cancer. 2015 Nov;6(6):800-4. doi: 10.1111/1759-7714.12217.

13.

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.

Isaka T, Yokose T, Ito H, Nagata M, Furumoto H, Nishii T, Katayama K, Yamada K, Nakayama H, Masuda M.

Medicine (Baltimore). 2015 Oct;94(42):e1784. doi: 10.1097/MD.0000000000001784.

14.

Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.

Stamatkin C, Ratermann KL, Overley CW, Black EP.

Cancer Biol Ther. 2015;16(9):1341-52. doi: 10.1080/15384047.2015.1070986.

15.

Switching off malignant pleural effusion formation-fantasy or future?

Spella M, Giannou AD, Stathopoulos GT.

J Thorac Dis. 2015 Jun;7(6):1009-20. doi: 10.3978/j.issn.2072-1439.2015.05.20. Review.

17.

Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.

Zhen Q, Liu JF, Liu JB, Wang RF, Chu WW, Zhang YX, Tan GL, Zhao XJ, Lv BL.

Cancer Biol Ther. 2015;16(4):549-57. doi: 10.1080/15384047.2015.1016689.

18.

Em08red, a dual functional antiproliferative emodin analogue, is a downregulator of ErbB2 expression and inducer of intracellular oxidative stress.

Liang FP, Lien JC, Wu YH, Chen CS, Juang SH.

Drug Des Devel Ther. 2015 Mar 12;9:1499-510. doi: 10.2147/DDDT.S66647.

19.

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.

Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A.

Mol Cancer. 2015 Jan 21;14:4. doi: 10.1186/1476-4598-14-4.

20.

Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.

Towse A, Ossa D, Veenstra D, Carlson J, Garrison L.

J Pers Med. 2013 Oct 25;3(4):288-305. doi: 10.3390/jpm3040288. Review.

Items per page

Supplemental Content

Support Center